Meropenem Bradex (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the final cross‑linking step of peptidoglycan formation, causing cell‑wall weakness, osmotic lysis, and rapid bacterial death. Its structure also confers resistance to most β‑lactamases.

The dosing regimen for Meropenem Bradex is determined by the prescribing clinician based on infection severity, pathogen susceptibility, patient weight, renal function, and other clinical factors. Only a qualified healthcare professional should set the appropriate dose.

Safety data in pregnancy and lactation are limited. Meropenem should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case individually and discuss risks with the patient.

To place an order, submit an enquiry on the Meropenem Bradex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meropenem offers a broad spectrum similar to imipenem‑cilastatin and ertapenem but has a slightly higher activity against Pseudomonas aeruginosa and better stability against many β‑lactamases. Choice among carbapenems depends on local resistance patterns, dosing convenience, and patient‑specific factors such as renal function.

Meropenem Bradex should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Meropenem Bradex is given by intravenous infusion. The infusion rate and duration are set by the treating physician, typically over 15‑30 minutes, and may be adjusted according to the patient’s renal function and clinical response.

Serious adverse events include anaphylaxis, severe seizures (especially in patients with renal impairment), Clostridioides difficile‑associated colitis, and significant hepatic or renal dysfunction. Prompt recognition and discontinuation are essential if any of these reactions occur.

Meropenem Bradex is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting medications listed under major interactions.